Monitoring estimated oxygen variation (EOV) using a wearable fitness tracker may facilitate early detection of coronavirus disease 2019 (COVID-19) symptom exacerbation and prevent untimely death, according to a new study.
Daily treatment with doxycycline did not shorten recovery time or reduce hospitalization or death in community-dwelling older adults with COVID-19, according to a study from the PRINCIPLE Collaborative Group.
Advisers to the US FDA* unanimously voted for emergency use authorization (EUA) of the Pfizer/BioNTech COVID-19 vaccine booster dose in people 65 years and older and those at high risk of severe COVID-19.
SARS-CoV-2 has evolved in a way that makes the virus more capable at spreading, shunning antibodies, or both. What is more is that this change appears to be favouring a more efficient viral aerosol generation, as shown in a recent study.
The administration of inhaled budesonide for the treatment of early COVID-19 in adults reduced the probability of needing urgent medical care and time to recovery, according to findings from the STOIC* trial presented at ERS 2021.
The use of colistimethate sodium (CMS), delivered via the I-neb, reduces pulmonary exacerbations among patients with bronchiectasis and chronic Pseudomonas aeruginosa (P. aeruginosa) infection, according to the PROMIS-1* study presented at ERS 2021.
Receiving an influenza vaccination after hospitalization for an invasive coronary procedure or a myocardial infarction (MI) may reduce the risk of all-cause or cardiovascular (CV) death, according to results of the IAMI* trial.
While both mRNA vaccines available on the market are strongly protective against SARS-CoV-2 infection and severe COVID-19 illness, emerging real-world data suggest that Moderna’s mRNA-1273 is more effective than Pfizer-BioNTech’s BNT162b2 vaccine in the face of Delta predominance.